The price of Amicus Therapeutics Inc (NASDAQ:FOLD) shares last traded on Wall Street rose 4.08% to $11.47.
Based on available information, 11 analysts follow Amicus Therapeutics Inc (NASDAQ:FOLD). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $21.00 and a low of $15.00, we find $20.00. Given the previous closing price of $11.02, this indicates a potential upside of 81.49 percent. FOLD stock price is now 5.02% away from the 50-day moving average and -4.01% away from the 200-day moving average. The market capitalization of the company currently stands at $3.36B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
Among analysts, 4 rate the stock a hold while 7 rate it a buy. Brokers who have rated the stock have averaged $18.78 as their price target over the next twelve months.
With the price target of $14, Morgan Stanley recently initiated with Equal-Weight rating for Amicus Therapeutics Inc (NASDAQ: FOLD).
In other news, Campbell Bradley L, President and CEO sold 11,702 shares of the company’s stock on Dec 01. The stock was sold for $129,693 at an average price of $11.08. Upon completion of the transaction, the President and CEO now directly owns 792,161 shares in the company, valued at $9.09 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 01, Executive Chairman Crowley John F sold 6,043 shares of the business’s stock. A total of $66,956 was realized by selling the stock at an average price of $11.08. This leaves the insider owning 883,791 shares of the company worth $10.14 million. Insiders disposed of 1,142,506 shares of company stock worth roughly $13.1 million over the past 1 year. A total of 3.08% of the company’s stock is owned by insiders.
A candlestick chart of Amicus Therapeutics Inc (NASDAQ: FOLD) showed a price of $11.02 on Thursday morning. During the past 12 months, Amicus Therapeutics Inc has had a low of $9.70 and a high of $14.10. As of last week, the company has a debt-to-equity ratio of 3.41, a current ratio of 2.73, and a quick ratio of 2.40. The fifty day moving average price for FOLD is $10.89 and a two-hundred day moving average price translates $11.94 for the stock.
The latest earnings results from Amicus Therapeutics Inc (NASDAQ: FOLD) was released for Sep, 2023. The net profit margin was -46.62% and return on equity was -130.63% for FOLD. The company reported revenue of $103.5 million for the quarter, compared to $81.69 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 26.7 percent.
Amicus Therapeutics Inc(FOLD) Company Profile
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children’s Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
